CWA
PTGX icon

CM Wealth Advisors’s Protagonist Therapeutics PTGX Stock Holding History

CM Wealth Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,285
Closed -$402K – 366
2023
Q1 		$402K Buy
+17,285
New +$290K 0.08% 286

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CM Wealth Advisors's PTGX Position: Q2 2023 in Review

CM Wealth Advisors sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 17,285 shares — an estimated $402K sold.

CM Wealth Advisors first reported a position in PTGX in Q1 2023 and held it in 1 quarter. The position peaked at $402K in Q1 2023. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • CM Wealth Advisors reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CM Wealth Advisors sold 17,285 Protagonist Therapeutics shares in Q2 2023, an estimated $402K.
  • CM Wealth Advisors first reported a position in Protagonist Therapeutics in Q1 2023 and held it in 1 quarter.
  • CM Wealth Advisors's Protagonist Therapeutics position peaked at $402K in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on CM Wealth Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.